# Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

> **NCT01722045** · PHASE4 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 154 (actual)

## Conditions studied

- Age - Related Macular Degeneration (AMD)

## Interventions

- **DRUG:** Intravitreal Aflibercept Injection (IAI)

## Key facts

- **NCT ID:** NCT01722045
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2017-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01722045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01722045, "Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT01722045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*